Investigating oxygen metabolism in diabetic retinopathy

研究糖尿病视网膜病变的氧代谢

• 批准号: 9185766
• 负责人: NADER SHEIBANI
• 金额: $ 46.84万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9185766
• 关键词: Address; Affect; Algorithms; Anatomy; Animal Model; Animals; Area; Attenuated; Biological Markers; Blindness; Blood capillaries; Blood flow; Clinical; Clinical Management; Complications of Diabetes Mellitus; Consumption; Control Animal; Decision Making; Development; Diabetes Mellitus; Diabetic Retinopathy; Diabetic mouse; Diagnosis; Disease; Electroretinography; Evaluation; Event; Eye; Functional Imaging; Functional disorder; Fundus photography; Goals; Image; Imaging technology; Impairment; Inflammatory Response; Intervention; Investigation; Ischemia; Knowledge; Lead; Left; Measurement; Measures; Metabolic; Metabolism; Methods; Modeling; Monitor; Optical Coherence Tomography; Outcome; Oxygen; Oxygen saturation measurement; Pathogenesis; Patients; Pattern; Phase; Protocols documentation; Retina; Retinal; Retinal Diseases; Rodent; Rodent Model; Role; Severities; Signal Pathway; Staging; System; Techniques; Technology; Testing; Therapeutic Intervention; Thrombospondin 1; Time; Translating; Translations; Variant; Vascular blood supply; Visible Radiation; Work; angiogenesis; base; blood glucose regulation; capillary; clinical Diagnosis; clinical practice; diabetic; diabetic patient; metabolic rate; mouse model; new technology; novel; prevent; quantitative imaging; response; retinal ischemia; retinal neuron; tool; treatment response; type I and type II diabetes

PROJECT SUMMARY Diabetic retinopathy (DR) is a leading cause of blindness in the US and one of the major complications of both Type 1 and Type 2 diabetes. Although DR is widely accepted to be an ischemia-driven disease, the current diagnosis and grading of DR severity is based solely on anatomic alterations such as the quantification of abnormal retinal microvasculature in non-proliferative disease or angiogenesis in proliferative stages. As a result, retinal impairment is irreversible in most DR patients when diagnosed, largely due to the lack of technology to quantify retinal ischemia and the lack of knowledge of the underlying mechanism of retinal ischemia. This proposal aims to investigate retinal ischemia in early diabetes using a novel optical coherence tomography technology, which offers the capability to quantify metabolic rate of oxygen (MRO2) in the retina for the first time. We refer to this new technology as visible-light optical coherence tomography or vis-OCT. We seek to identify when MRO2 alterations initially occur, the causes of MRO2 alterations, and whether intervention of MRO2 affects the development of DR in a unique Type 1 mouse model. At the end of the project period, we will have 1) established a time line and mechanistic knowledge of retinal MRO2 changes during the development and progression of DR and 2) fully-optimized the vis-OCT system that is ready to be translated for the next-stage patient testing.

项目概要 糖尿病视网膜病变 (DR) 是美国失明的主要原因，也是糖尿病视网膜病变的主要并发症之一 1 型和 2 型糖尿病。尽管 DR 被广泛认为是一种缺血驱动的疾病，但目前 DR 严重程度的诊断和分级仅基于解剖学改变，例如 非增殖性疾病中的视网膜微血管异常或增殖阶段的血管生成。作为一个 结果，大多数 DR 患者在诊断时视网膜损伤是不可逆转的，这主要是由于缺乏 量化视网膜缺血的技术和缺乏对视网膜潜在机制的了解 缺血。 该提案旨在利用新型光学相干性研究早期糖尿病中的视网膜缺血 断层扫描技术，能够量化视网膜中的氧代谢率 (MRO2) 第一次。我们将这种新技术称为可见光光学相干断层扫描或 vis-OCT。我们 寻求确定 MRO2 改变最初发生的时间、MRO2 改变的原因以及是否需要干预 MRO2 影响独特 1 型小鼠模型中 DR 的发展。在项目期结束时，我们 将 1) 建立视网膜 MRO2 变化的时间线和机制知识 DR 的开发和进展以及 2) 全面优化了准备翻译的 vis-OCT 系统 用于下一阶段的患者测试。